Autobio Diagnostics Future Growth
Future criteria checks 3/6
Autobio Diagnostics is forecast to grow earnings and revenue by 20.9% and 16% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 16.2% in 3 years.
Key information
20.9%
Earnings growth rate
20.7%
EPS growth rate
Medical Equipment earnings growth | 26.5% |
Revenue growth rate | 16.0% |
Future return on equity | 16.2% |
Analyst coverage | Good |
Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 6,503 | 2,022 | N/A | 2,198 | 6 |
12/31/2025 | 5,621 | 1,655 | N/A | 1,874 | 9 |
12/31/2024 | 4,754 | 1,347 | N/A | 1,620 | 8 |
9/30/2024 | 4,581 | 1,273 | 710 | 1,468 | N/A |
6/30/2024 | 4,543 | 1,291 | 575 | 1,429 | N/A |
3/31/2024 | 4,496 | 1,300 | 686 | 1,595 | N/A |
12/31/2023 | 4,444 | 1,217 | 569 | 1,470 | N/A |
9/30/2023 | 4,403 | 1,169 | 609 | 1,501 | N/A |
6/30/2023 | 4,479 | 1,180 | 656 | 1,525 | N/A |
3/31/2023 | 4,447 | 1,169 | 631 | 1,580 | N/A |
12/31/2022 | 4,442 | 1,167 | 620 | 1,558 | N/A |
9/30/2022 | 4,352 | 1,156 | 581 | 1,536 | N/A |
6/30/2022 | 4,159 | 1,095 | 508 | 1,508 | N/A |
3/31/2022 | 3,980 | 1,042 | 386 | 1,384 | N/A |
12/31/2021 | 3,766 | 974 | 395 | 1,461 | N/A |
9/30/2021 | 3,626 | 950 | 467 | 1,608 | N/A |
6/30/2021 | 3,450 | 887 | 125 | 1,339 | N/A |
3/31/2021 | 3,245 | 826 | -23 | 1,191 | N/A |
12/31/2020 | 2,978 | 748 | -121 | 995 | N/A |
9/30/2020 | 2,833 | 751 | -361 | 630 | N/A |
6/30/2020 | 2,706 | 728 | -202 | 717 | N/A |
3/31/2020 | 2,682 | 746 | -35 | 797 | N/A |
12/31/2019 | 2,679 | 774 | 81 | 843 | N/A |
9/30/2019 | 2,463 | 689 | 44 | 754 | N/A |
6/30/2019 | 2,261 | 636 | 142 | 685 | N/A |
3/31/2019 | 2,062 | 588 | 216 | 650 | N/A |
12/31/2018 | 1,930 | 563 | 244 | 654 | N/A |
9/30/2018 | 1,777 | 534 | 215 | 566 | N/A |
6/30/2018 | 1,666 | 502 | N/A | 537 | N/A |
3/31/2018 | 1,574 | 475 | N/A | 507 | N/A |
12/31/2017 | 1,400 | 447 | N/A | 482 | N/A |
9/30/2017 | 1,271 | 419 | N/A | 501 | N/A |
6/30/2017 | 1,129 | 393 | N/A | 461 | N/A |
3/31/2017 | 1,030 | 363 | N/A | 444 | N/A |
12/31/2016 | 980 | 350 | N/A | 416 | N/A |
9/30/2016 | 898 | 335 | N/A | 360 | N/A |
6/30/2016 | 837 | 317 | N/A | 371 | N/A |
3/31/2016 | 752 | 278 | N/A | 313 | N/A |
12/31/2015 | 716 | 278 | N/A | 309 | N/A |
12/31/2014 | 563 | 208 | N/A | 257 | N/A |
12/31/2013 | 409 | 124 | N/A | 103 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603658's forecast earnings growth (20.9% per year) is above the savings rate (2.8%).
Earnings vs Market: 603658's earnings (20.9% per year) are forecast to grow slower than the CN market (26.2% per year).
High Growth Earnings: 603658's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603658's revenue (16% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 603658's revenue (16% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603658's Return on Equity is forecast to be low in 3 years time (16.2%).